Strengthening the Regulation of Dietary Supplements—Lessons from Prevagen®
Update Magazine | Winter 2021
FDA Emergency Use Authorization: A Brief History From 9/11 to COVID-19
Update Magazine | Fall 2021
Can Food Labeling Policy Advance Health Equity?
Update Magazine | Fall 2021
Fido Has it All Figured Out: Lessons Learned from Animal Supplements May be Useful to Those Seeking a Human CBD Supplement Pathway
Update Magazine | Fall 2021
Biosimilar Strength vs. Potency: Avoiding a Regulatory Hobson’s Choice
Update Magazine | Fall 2021
Will FDA Extend Its Proposed Ban on Menthol Cigarettes and Characterizing Flavors in Cigars to Flavored ENDS Products?
Update Magazine | Fall 2021
FDA Drug Manufacturing Oversight During Covid-19: The GAO Report on the Inspections Backlog and Steps FDA is Taking to Address It
Update Magazine | Summer 2021
Orphan Drugs in Canada: A “One Size Fits All” Regulatory Regime
Orphan Drugs in Canada: A “One Size Fits All” Regulatory Regime By Eileen McMahon and Denise Ramsden Introduction Medicines targeting rare diseases, also known as orphan drugs,[1] once faced an uphill battle for research funding and market approval. The need for robust commercial incentives to create rare disease treatments spurred the establishment [...]
Food and Supplement Class Action Suits That Rely on Alleged Regulatory Violations
Update Magazine | Summer 2021
Pharmaceutical GMPs, Quality Control, and Data: A Deeper Look at FDA’s FY 2020 FDA Observations
Update Magazine | Summer 2021
